Press Release
Pharma eReport delivers V5-compliant solution to help MAHs meet December 31st XEVMPD resubmission deadline
Centrality software is fully compliant with EMA V5 schema updates and available now to pharmaceutical Marketing Authorisation Holders
Cambridge, UK, September 15th 2014—Pharma eReport, a software and services company that delivers a comprehensive XEVMPD compliance solution for pharmaceutical regulatory professionals, today announces that its Centrality software is fully compliant with the latest XEVMPD schema changes mandated by the European Medicines Agency (EMA). Centrality offers Marketing Authorisation Holders a straightforward mechanism to import existing product data, update it to the new V5 schema and submit it to the EMA. The software has been successfully managing the re-submission process for customers since the V5 update came into force on 16th June 2014. Prospective users can register for a free online demonstration now at http://www.pharmereport.com.
On January 31st 2014, the EMA substantially changed the requirements for the product data that pharmaceutical companies must submit to the Eudravigilance Medicinal Product Dictionary, or XEVMPD. All Marketing Authorisation Holders (MAHs) must have updated their product records in accordance with the EMA’s “V5” guidance by December 31st 2014. The mandatory changes are being made to address a range of issues on the road to the implementation of ISO IDMP (Identification of Medicinal Products) in 2016, including new information required to support the assignment of pharmacovigilance fees, improvements to the quality of submitted data, and modification of controlled vocabularies.
Pharma eReport’s quality-assured, V5-compliant Centrality software is being used today by major global pharmaceutical companies to manage ongoing XEVMPD compliance. Built directly from the EMA schema to ensure syntactically correct EudraVigilance Product Report Message (EVPRM) messages by construction, Centrality also incorporates built-in business rules, so that the entire process – from data entry through to submission to the EMA gateway – is error-free, continuously cross-checked and seamlessly compliant.
Pharma eReport’s solution offers extensive data import capabilities and transparently interfaces with customers’ existing data systems. With the additional option of a full range of specialist support and consulting services, Pharma eReport enables customers to outsource the entire XEVMPD compliance process.
Commenting on today’s announcement, Marco Rubinstein, CEO of Pharma eReport said: "Our Centrality software is being embraced by major pharmaceutical companies as a technically superior, cost-effective and proven solution to achieving and maintaining XEVMPD compliance.” He added: “Since our solution has been engineered from the ground up to be both agile and highly robust, we have been able to very quickly adapt our system to the requirements of the V5 update. Whether MAHs are currently using the EV web tool, a different software solution, or even have yet to submit any data to the EMA, we provide a complete, easy-to-implement and fully tested solution for Article 57 compliance that minimises the administrative burden and keeps pace with evolving specifications.”
The Centrality software is offered via a transparent pricing model and with fully flexible deployment options. The Centrality platform is available as a secure, on-demand cloud-based application (Software-as-a-service) accessed via a standard web browser, or it can be installed as a standalone software application. For customers who wish to have all their data in-house, Centrality can be installed on a company intranet, so that the data is held on-site and authorised users can access it securely via the company system. The Centrality software solution is completely independent – no other software needs to be installed – and offers full support for both Windows and Linux.
To sign-up online for a free demonstration of Pharma eReport’s Centrality software, please visit: http://www.pharmaereport.com
---ends---
Press contacts
Nicky Denovan
Pharma eReport
nicky [at] pharmaereport [dot] com
Phone: +44 (0) 7747 017654
About Pharma eReport (http://www.pharmaereport.com)
Cambridge, UK-based Pharma eReport provides intuitive electronic product data management and reporting software for pharmaceutical regulatory professionals.
With its Centrality software and supporting specialist XEVMPD services – delivered by a Key Support Services team of qualified chemists – Pharma eReport provides a comprehensive XEVMPD solution, including complete outsourced data collation, organisation and mapping capabilities. The Centrality software is available as an on-demand software-as-a-service (SaaS)/cloud-based solution – accessed via a standard web browser – or it can be installed as a standalone software application at a client site.
Pharma eReport is co-founded by the management of ELC Group – a leading global services company with recognised expertise in regulatory affairs and Marketing Authorisation management – plus former executives from electronic design automation software company Synopsys, Inc. Pharma eReport harnesses the unparalleled industry knowledge of its regulatory expert founders and combines this with a world-class software development team to deliver a total solution for XEVMPD compliance and beyond.
Also see our
press coverage
News Index
11 Feb 2019
Garth Hedenskog joins ELC Group to expand global sales
26 Nov 2018
Industry plans for disruption amid Brexit uncertainty
25 Oct 2018
ELC Group at 5th Nordic Pharmacovigilance Day - Oct 24th, Copenhagen
05 Oct 2018
EU/US MRA - Brief overview and update
21 Aug 2018
Brexit - has the music stopped?
13 Jul 2018
15 Jun 2018
08 May 2018
MHRA sets its post-Brexit strategic direction
12 Apr 2018
20 Mar 2018
Clinical Trials: all change 2019
22 Jan 2018
Orphan Medicines: almost 20 years on
15 Dec 2017
05 Oct 2017
How recent moves by the FDA spell good news for generics in the US
11 Sep 2017
Medicines for the Elderly – is your drug development strategy up to the mark?
14 Aug 2017
The MNAT initiative – what’s new?
19 Jul 2017
ICH Q12: Light at the end of the tunnel…?
05 Jun 2017
Q3D: Are your established products in compliance?
02 Jun 2017
Key pharmacovigilance trends to watch
08 May 2017
10 Apr 2017
New EMA Consultation on the Quality of Inhaled Pharmaceutical Products
16 Mar 2017
European Parliament’s adoption of ‘Options for improving access to medicines’ procedure
16 Feb 2017
Article 58: a hidden potential
24 Jan 2017
Global lifesciences partner ELC Group teams with PSR Group for advanced drug development
19 Jan 2017
A positive step forward for Biosimilar registration
20 Dec 2016
Falsified Medicines Directive – Are you making the right preparations?
21 Nov 2016
New Public consultation launched by the European Commission (EC)
19 Oct 2016
Transatlantic collaboration to boost research and development of medicines for rare diseases
03 Jun 2016
ELC Group to showcase regulatory affairs solutions at CPhI events in Shanghai and Barcelona
16 Jun 2015
ELC Group in early-stage development of novel influenza vaccine
09 Jun 2015
ELC Group expands into pharmaceutical product development market
21 Apr 2015
ELC Group signs 1.5 million Euro regulatory affairs contract with Chinese pharma giant
24 Feb 2015
02 Feb 2015
ELC GROUP to present at “Regulatory & Legal Affairs in Russia 2015” Conference
15 Sep 2014
20 Aug 2014
ELC Group Appoints Dr. Siddharth Chachad as Head of Global Clinical Development and Medical Affairs
28 Jul 2014
ELC Group Appoints Head of Regulatory Affairs for Russia and CIS
14 Apr 2014
10 Oct 2013
17 Sep 2013
Global regulatory affairs specialist ELC Group appoints former MHRA Expert Medical Assessor
23 Apr 2013
27 Feb 2013
Global regulatory affairs specialist ELC Group to deliver pharmaceutical training event in Latvia
20 Feb 2013
Global pharmaceutical regulatory affairs specialist ELC Group launches Clinical Trials services
10 Jan 2013
31 Dec 2012
07 Nov 2012
Global pharmaceutical regulatory affairs specialist ELC Group establishes new office in Singapore
22 Aug 2012
12 Jun 2012
XEVMPD software provider Pharma eReport launches Excel Data Import Service
06 Jun 2012
28 Mar 2012
ELC Group joins DIA EuroMeeting in Copenhagen
21 Mar 2012
08 Mar 2012
ELC Group Hosts Successful International Regulatory Seminar
06 Mar 2012
Pharmaceutical regulatory affairs specialist ELC Group opens new office in Mumbai
23 Feb 2012
Regulatory challenges for 2012 and their impact on marketing authorisation
21 Feb 2012
08 Feb 2012
Pharmaceutical regulatory affairs specialist ELC Group establishes global HQ in Cambridge, UK
07 Dec 2011
27 Sep 2011
12 Jul 2011
ELC Group aim to foster strategic and economic ties within India and China
25 May 2011
ELC Group announces doubled revenues
11 May 2011